Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.

The diabetic macular edema section is a comprehensive resource for Ophthalmology news and expert insights. Read more at Modern Retina.

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.